[
    [
        {
            "time": "2023-03-15",
            "original_text": "Trading Johnson & Johnson Once It Reports Earnings",
            "features": {
                "keywords": [
                    "Johnson & Johnson",
                    "Earnings"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "Correlation": 9,
                "Sentiment": 5,
                "Importance": 6,
                "Impact": 7,
                "Duration": 3,
                "Entity_Density": 8,
                "Market_Scope": 2,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 6
            }
        },
        {
            "time": "2023-03-15",
            "original_text": "J&J's Tremfya Receives FDA Approval for Psoriatic Arthritis",
            "features": {
                "keywords": [
                    "Tremfya",
                    "FDA Approval",
                    "Psoriatic Arthritis"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 8,
                "Impact": 8,
                "Duration": 6,
                "Entity_Density": 9,
                "Market_Scope": 3,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        },
        {
            "time": "2023-03-15",
            "original_text": "Johnson & Johnson Is Poised (Again) for an Upside Breakout",
            "features": {
                "keywords": [
                    "Johnson & Johnson",
                    "Upside Breakout"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "Correlation": 8,
                "Sentiment": 7,
                "Importance": 7,
                "Impact": 6,
                "Duration": 4,
                "Entity_Density": 8,
                "Market_Scope": 2,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 6
            }
        },
        {
            "time": "2023-03-15",
            "original_text": "Markets open higher on COVID-19 vaccine hopes",
            "features": {
                "keywords": [
                    "Markets",
                    "open higher",
                    "COVID-19",
                    "vaccine hopes"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare",
                    "general market"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "Correlation": 4,
                "Sentiment": 7,
                "Importance": 6,
                "Impact": 5,
                "Duration": 5,
                "Entity_Density": 3,
                "Market_Scope": 9,
                "Time_Proximity": 8,
                "Headline_Structure": 6,
                "Source_Recency": 7
            }
        },
        {
            "time": "2023-03-15",
            "original_text": "Why Earnings Season Could Be Great for Johnson & Johnson (JNJ)",
            "features": {
                "keywords": [
                    "Earnings Season",
                    "Johnson & Johnson"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "Correlation": 8,
                "Sentiment": 6,
                "Importance": 7,
                "Impact": 6,
                "Duration": 4,
                "Entity_Density": 8,
                "Market_Scope": 2,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 6
            }
        },
        {
            "time": "2023-03-15",
            "original_text": "The Zacks Analyst Blog Highlights: Pfizer, BioNTech, Moderna, Novavax and Johnson & Johnson",
            "features": {
                "keywords": [
                    "Zacks Analyst Blog",
                    "Pfizer",
                    "BioNTech",
                    "Moderna",
                    "Novavax",
                    "Johnson & Johnson"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "Correlation": 6,
                "Sentiment": 5,
                "Importance": 5,
                "Impact": 4,
                "Duration": 5,
                "Entity_Density": 7,
                "Market_Scope": 8,
                "Time_Proximity": 7,
                "Headline_Structure": 6,
                "Source_Recency": 6
            }
        },
        {
            "time": "2023-03-15",
            "original_text": "The Daily Biotech Pulse: Moderna To Kickstart Phase 3 Study On July 27, Immutep Awarded Antibody Patent",
            "features": {
                "keywords": [
                    "Moderna",
                    "Phase 3 Study",
                    "Immutep",
                    "Antibody Patent"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "Correlation": 3,
                "Sentiment": 6,
                "Importance": 5,
                "Impact": 4,
                "Duration": 5,
                "Entity_Density": 4,
                "Market_Scope": 7,
                "Time_Proximity": 7,
                "Headline_Structure": 6,
                "Source_Recency": 6
            }
        }
    ]
]